Summary of Key Information:

Reporting Period: Quarter and Half Year Ended September 30, 2026 (Q2 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results

Date of Board Meeting / Approval: October 29, 2026 (Commenced at 2:35 PM, concluded at 3:42 PM)

Audit Opinion: Unmodified conclusion (clean opinion) by statutory auditors Price Waterhouse Chartered Accountants LLP

Auditor's Comment: No qualifications or modifications. Nothing came to their attention that causes them to believe the financial results contain material misstatement.

Key Financial Highlights [Rs. in Crores]

Standalone Results:

Revenue from Operations:

  • Q2 FY27: ₹256.25 crore (Up 26.7% YoY from ₹202.23 crore in Q2 FY26)
  • H1 FY27: ₹481.91 crore (Up 26.4% YoY from ₹381.12 crore in H1 FY26)

Total Income:

  • Q2 FY27: ₹259.19 crore
  • H1 FY27: ₹488.36 crore

Net Profit:

  • Q2 FY27: ₹48.13 crore (Up 11.9% YoY from ₹43.03 crore)
  • H1 FY27: ₹98.30 crore (Up 24.3% YoY from ₹79.08 crore)

EPS:

  • Basic EPS Q2 FY27: ₹3.03 (not annualized)
  • Diluted EPS Q2 FY27: ₹3.02 (not annualized)
  • Basic EPS H1 FY27: ₹6.18 (not annualized)
  • Diluted EPS H1 FY27: ₹6.16 (not annualized)

Other Equity: ₹399.13 crore as of September 30, 2026 (vs ₹401.51 crore as of March 31, 2026)

Cash and Cash Equivalents: ₹16.98 crore as of September 30, 2026 (vs ₹32.88 crore as of March 31, 2026)

Debt: Not specifically disclosed as total debt, but includes:

  • Lease liabilities: ₹53.20 crore (₹43.43 crore non-current + ₹9.77 crore current)
  • Other financial liabilities: ₹24.76 crore (₹5.00 crore non-current + ₹19.76 crore current)

Consolidated Results:

Revenue from Operations:

  • Q2 FY27: ₹270.81 crore (Up 25.1% YoY from ₹216.53 crore)
  • H1 FY27: ₹510.83 crore (Up 24.7% YoY from ₹409.56 crore)

Total Income:

  • Q2 FY27: ₹274.44 crore
  • H1 FY27: ₹518.61 crore

Net Profit:

  • Q2 FY27: ₹15.22 crore (Down 68.2% YoY from ₹47.81 crore) [Due to exceptional impairment]
  • H1 FY27: ₹66.55 crore (Down 22.7% YoY from ₹86.10 crore)

EPS:

  • Basic EPS Q2 FY27: ₹0.96 (not annualized)
  • Diluted EPS Q2 FY27: ₹0.95 (not annualized)
  • Basic EPS H1 FY27: ₹4.18 (not annualized)
  • Diluted EPS H1 FY27: ₹4.16 (not annualized)

Other Equity: ₹394.26 crore as of September 30, 2026 (vs ₹426.33 crore as of March 31, 2026)

Cash and Cash Equivalents: ₹21.90 crore as of September 30, 2026 (vs ₹38.32 crore as of March 31, 2026)

Segment-wise Performance [Rs. in Crores]:

Diagnostic Testing Services:

  • Q2 FY27 Revenue: ₹256.74 crore (Up 27.4% YoY)
  • Q2 FY27 Segment Profit: ₹71.52 crore

Imaging Services:

  • Q2 FY27 Revenue: ₹13.55 crore (Down 4.6% YoY)
  • Q2 FY27 Segment Profit: ₹2.09 crore

Others:

  • Q2 FY27 Revenue: ₹0.52 crore (Down 32.5% YoY)
  • Q2 FY27 Segment Profit: ₹0.59 crore

Corporate Actions:

Dividend: The cash flow statement shows dividend paid to shareholders of ₹111.42 crore for H1 FY27.

Subsidiary Sale: Board approved on September 21, 2026, the proposed sale of entire shareholding in Nueclear Healthcare Limited (wholly owned subsidiary) for aggregate consideration of approximately ₹141.40 crore (cash and Compulsorily Convertible Preference Shares), subject to working capital adjustments and shareholder approval.

Other Significant Information:

Employee Stock Options: During Q2 FY27, the company forfeited 6,649 equity stock options due to employee discontinuation, which were added back to the pool for future distribution.

Accounting Policies: Financial results prepared in accordance with Ind AS 34 "Interim Financial Reporting" and comply with SEBI Listing Regulations.

Assets Position:

  • Standalone total assets: ₹714.42 crore as of September 30, 2026
  • Consolidated total assets: ₹725.13 crore as of September 30, 2026